Fig 2: PGK1-HTATSF1 expression as a prognostic factor for clinical lung cancer patients.A PGK1 and HTATSF1 protein expression in the paired normal and tumor tissues derived from clinical lung cancer patients. Statistical significance was analyzed by a paired t-test. Scale bar: 400 µm. B IHC staining for the PGK1 protein. The intensity of IHC staining was scored as a range from 0 to 3. Scale bar: 50 µm. C Quantification of HTATSF1 expression by immunohistochemistry analysis of lung cancer specimens by each corresponding clinical parameter. D PGK1 protein expression in several tumor tissues derived from clinical lung cancer patients. Scale bar: 400 µm. 20x: 200µm.E Kaplan–Meier analysis of the overall survival and disease-free survival probabilities of clinical lung cancer patients according to the intensity (low = 0 and 1, high = 2 and 3) of IHC staining for the PGK1 protein combined with the HTATSF1 protein level.

Fig 3: The binding affinity of PGK1-HTATSF1 reflects the lung cancer migration ability.A The crystal structure of PGK1 includes two domains and a 3-PG/ADP binding site (PDB ID:2XE7). B Sequences of the amino acids of the PGK1 wild-type gene, primer and several mutant forms that were designed. C Intracellular phosphoglycerate kinase activity of the PGK1 overexpression model. D Intracellular phosphoglycerate kinase activity in H1355 cells after the forced expression of exogenous wild-type or mutant PGK1 genes. E Pull-down assay for whole cell lysates derived from H1355 cells with the forced expression of exogenous wild-type (wt) or mutant PGK1 using beads followed by western blot analysis of the HTATSF1 and PGK1 proteins. F Cellular migration abilities of H1355 cells after the forced expression of exogenous wild-type or mutant PGK1. The symbol ***p < 0.001 in the nonparametric Mann–Whitney test.